Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:01 AM
Ignite Modification Date:
2025-12-25 @ 12:01 AM
NCT ID:
NCT02730858
Eligibility Criteria:
Inclusion Criteria
* Diagnosed with metastatic breast cancer and:
1. have been informed of a diagnosis of leptomeningeal disease in the past eight weeks; OR
2. have been informed of a diagnosis of progressive brain metastases after initial radiation therapy in the past eight weeks; OR
3. have been diagnosed brain metastases and began whole brain radiation in the past eight weeks; OR
4. had an unplanned hospital admission and was discharged within the past eight weeks; OR
5. have been diagnosed with triple negative breast cancer and started second-line treatment in the past eight weeks; OR
6. have started the third regimen in one year within the past eight weeks; OR
7. have HER2+ disease and started third-line therapy within the past eight weeks; OR
8. have ER+ disease and started third-line chemotherapy within the past eight weeks; OR
9. enrolled on a clinical trial within the past eight weeks
* Receiving cancer care at MGH Cancer Center.
* Able to read and write in English.
* Eastern Cooperative Oncology Group status between 0 and 2.
Exclusion Criteria:
* Already receiving palliative care in the outpatient setting.
* Active, untreated, unstable, serious mental illness (e.g., active, untreated psychotic, bi-polar, or substance-dependence disorder) interfering with ability to participate.
* Cognitive impairment (e.g., delirium, dementia) interfering with ability to participate.
* Requires urgent palliative or hospice care.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02730858
Study Brief:
Protocol Section:
NCT02730858